April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review discusses the potential of nanocarriers like liposomes and nanoparticles to enhance the delivery and efficacy of treatments for androgenetic alopecia, while noting the challenges of clinical translation, such as securing reliable trials and regulatory approval.
May 2025 in “International Journal of Applied Pharmaceutics” This review highlights the potential of nanotechnology in enhancing the treatment of androgenetic alopecia by facilitating targeted drug delivery, improving drug stability, and increasing concentration at target sites, although clinical validation and scalable manufacturing are needed for practical implementation.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review highlights the potential of nanocarriers, like liposomes and solid lipid nanoparticles, in improving targeted drug delivery and effectiveness for androgenetic alopecia treatment, while noting the hurdles of clinical trials and regulatory approval for these advanced methods.
This study systematically reviewed androgenetic alopecia's clinical features, mechanisms, and treatments, highlighting that current drugs have limitations but emerging therapies and personalized treatment strategies could enhance efficacy and outcomes.
August 2026 in “Journal of Dermatologic Science and Cosmetic Technology” In this review, researchers critically examine contemporary treatments for androgenetic alopecia, emphasizing advanced drug delivery systems, regenerative medicine, and emerging molecular targets, while identifying significant gaps that hinder translating these innovations into clinical practice.
